Infant Bacterial Therapeutics (IBT) investor relations material

Executive summary

• No net sales were recorded for Q1 2026, with continued focus on drug development and regulatory progress for IBP-9414.

• Operating loss increased to KSEK -23,499 compared to KSEK -17,495 in Q1 2025, mainly due to higher validation and regulatory costs.

• The company is preparing for a Biologics License Application (BLA) submission to the FDA in 2026, following constructive regulatory dialogue.

• Final product validation and preparations for commercialization are underway, with parallel registration efforts in Europe.

Financial highlights

• Operating loss for Q1 2026 was KSEK -23,499, up from KSEK -17,495 year-over-year.

• Result after tax was KSEK -22,935, compared to KSEK -16,739 in Q1 2025.

• Cash flow for the period was KSEK -12,419, an improvement from KSEK -27,979 in Q1 2025.

• Cash balance at March 31, 2026, was KSEK 131,929, down from KSEK 191,758 a year earlier.

• Equity per share was SEK 6.13, and the equity ratio was 58% at quarter-end.

Outlook and guidance

• Plans to submit a BLA to the FDA in 2026, with ongoing regulatory discussions and manufacturing validation.

• Commercial launch preparations are ongoing, including selection of packaging and distribution partners in the US and Europe.

• Capital is considered sufficient until market approval is obtained.